Quick Facts

• Targeted relief: Supports the management of symptoms associated with seasonal and perennial allergic rhinitis (hay fever).
• Relief domains: Helps reduce sneezing, runny nose, and nasal itching.
• Ocular relief: Assists in alleviating itchy, burning, and watery eyes.
• Skin support: Provides symptomatic relief for chronic idiopathic urticaria (hives or nettle rash).

Loratadina Ranbaxy provides symptomatic relief for conditions related to upper respiratory and skin allergies. It is approved for the management of symptoms associated with allergic rhinitis, commonly known as hay fever. This includes helping to reduce issues such as sneezing, a runny nose, and nasal itching. The medication also supports the temporary alleviation of ocular symptoms, specifically itchy, burning, and watery eyes.

Furthermore, Loratadina Ranbaxy is used in the treatment of chronic idiopathic urticaria. In this context, it may contribute to the temporary alleviation of associated itching, redness, and hives (wheals). The drug is intended to assist in the overall symptom control of these allergic manifestations, promoting comfort during episodes.

Who can and cannot use Loratadina Ranbaxy?

The official regulatory documents establish specific population eligibility criteria for the use of Loratadina Ranbaxy. These criteria determine which groups are allowed to use the medicine and which are formally restricted or contraindicated.

---

Populations That Must Not Use the Medicine (Contraindications)

• Hypersensitivity: The medicine is formally contraindicated for patients with a known allergy or hypersensitivity to the active substance, loratadine, or to any of the excipients in the specific formulation.
• Metabolic Disorders: Patients with rare hereditary problems, such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption, are contraindicated from using the lactose-containing tablet formulation.

---

Age and Physiological Status Eligibility

Population Group	Eligibility Status	Regulatory Requirement
Adults & Adolescents	Eligible	Standard use (typically 12 years)
Children (< 2 years)	Not established	Safety and efficacy have not been established
Severe Organ Impairment	Conditional use	Caution and a reduced initial dose are required for severe hepatic or renal impairment
Pregnant Women	Not recommended	Avoidance is preferable as a precautionary measure
Breastfeeding Women	Not recommended	The drug is excreted into breast milk

These guidelines define the boundaries for safe and appropriate use, ensuring the medicine is only administered to populations with an established regulatory profile.

Interactions with other medicines and products

Loratadine is metabolized in the liver, primarily by the cytochrome P450 enzymes CYP3A4 and, to a lesser extent, CYP2D6. Due to this metabolic pathway, the potential exists for interactions with other medicinal products that inhibit these specific enzymes.

Key Drug Interactions

Interacting Product Category	Mechanism and Effect
CYP3A4/CYP2D6 Inhibitors (e.g., Ketoconazole, Erythromycin, Cimetidine)	These medicines may significantly reduce the breakdown of loratadine, resulting in substantially increased plasma concentrations of loratadine and its active metabolite. While clinical studies with these specific drugs have reported increased levels, they generally did not show associated clinically significant changes in the overall safety profile, including cardiac effects.
Other Medicines	Products known to cause side effects such as drowsiness, dry mouth, or difficulty urinating should be used with caution, as taking loratadine could potentially worsen these effects.

Interaction-Related Constraints

• Allergy Skin Tests: Loratadine may interfere with the results of tests used to check for allergies. It is generally recommended to discontinue the administration of loratadine at least 48 hours before any planned allergy skin tests.
• Alcohol: Although loratadine does not typically potentiate the effects of alcohol on psychomotor performance, it is advisable to limit alcohol consumption as it may increase the risk of experiencing drowsiness.

Patients with severe liver impairment may be at higher risk for increased loratadine levels due to reduced clearance, which requires special consideration regarding dosage.

Loratadine is classified as a second-generation tricyclic compound that functions as a selective inverse agonist of peripheral histamine H1-receptors. These H1-receptors are G-protein coupled receptors that naturally exist in a dynamic equilibrium between active and inactive states. Loratadine and its active metabolite preferentially bind to and stabilize the inactive conformation of the H1-receptor, consequently preventing the binding of endogenous histamine. This molecular interaction primarily occurs in peripheral tissues, as the molecule minimally crosses the blood-brain barrier.

Upon systemic absorption, loratadine undergoes rapid first-pass hepatic metabolism, primarily facilitated by the cytochrome P450 isoenzymes CYP3A4 and CYP2D6. This biotransformation yields the active metabolite, desloratadine, which also contributes to the inverse agonism at the peripheral histamine H1-receptor.

The compound and its metabolite also exert H1-receptor-independent actions. They have been shown to influence intracellular signaling pathways, including the suppression of NF-κB transcriptional activity. This modulation consequently affects the release of pro-inflammatory mediators such as cytokines and chemokines from mast cells and basophils, which alters downstream cellular responses.

The administration of Loratadina is based on a once-daily oral schedule to provide 24-hour coverage. The standard dose for adults and children 6 years of age and older is 10 mg taken once every day, with a clear maximum of 10 mg in a 24-hour period. Dosing for the pediatric population from 2 to less than 6 years is set at 5 mg once daily, typically administered via a liquid or syrup formulation for accurate measurement.

A key instruction regarding timing is that the medicine can be taken without regard to mealtime, offering flexibility in its placement within the user’s daily routine. Furthermore, specific modifications exist for certain populations: for adults and children 6 years and older with severe hepatic or renal impairment (GFR < 30 mL/min), the dosing interval is adjusted to 10 mg every other day to account for reduced drug clearance.

The method of intake is dependent on the dosage form: standard tablets are swallowed whole, while Orally Disintegrating Tablets (ODT) must be allowed to fully dissolve on the tongue. A crucial procedural requirement for the course of use is the discontinuation of loratadine for a minimum of 48 hours before allergy skin tests, a necessary step to prevent interference with the dermal reactivity index.

Research evidence / Overview of studies for Loratadina Ranbaxy

---

Evidence for Use in Allergic Rhinitis (Hay Fever)

Research examining loratadine for conditions characterized by fluctuating allergic manifestations has relied primarily on randomized controlled trials (RCTs) and systematic reviews. Studies examined a set of outcomes related to physical discomfort, specifically monitoring symptoms such as sneezing, nasal itching, and ocular symptoms (itchy or watery eyes). Studies reported measurements of how these core symptoms evolved in the observed populations during short-term trials. What remains uncertain, however, is the full extent of the measured effect on nasal congestion (stuffiness), which may be limited compared to outcomes related to other symptom components.

---

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

Loratadine was studied for its role in managing acute, disruptive episodes such as chronic idiopathic urticaria (hives) using controlled clinical trial designs. Research examined patient-reported outcomes for perceived discomfort, focusing primarily on measuring changes in the size and number of wheals (hives) and the intensity of pruritus (itching). Studies monitored how symptoms evolved in the observed populations over defined intervals, typically four to six weeks. Research provides context for short-term changes for conditions involving periods of heightened symptoms.

---

Duration of Evidence and Long-Term Follow-up

The primary body of evidence used to establish the initial understanding of loratadine was observed in trials with short-term follow-up durations, typically lasting two to six weeks. While these studies are relevant for assessing episodic symptom patterns, there is limited information for long-term outcomes. Research exploring maintenance is not as extensive as the short-term efficacy data, meaning the full profile of sustained patterns over many months or years is less characterized by large-scale controlled trials.

---

Evidence in Special Populations

Research was conducted in various age groups, such as the pediatric patient population (children as young as 2 years old). Loratadine was evaluated in research applied in studies examining patient-reported experiences and monitoring symptoms in these younger groups. The results apply only to the populations studied. Data for certain subgroups, such as children with specific comorbidities, remain insufficient compared to the general adult population.

---

What Remains Uncertain About the Research

Review of the evidence base highlights that comparative evidence is lacking for direct, high-quality comparisons against all second-generation antihistamines. Certainty remains low regarding its precise ranking for overall outcomes across all possible symptom axes. Lastly, the focus on short-term trials means that long-term effects are not fully established, and there is limited information on the durability of the observed patterns over many months of monitoring.

Key Studies & References Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834) - ClinicalTrials.gov

Common questions about Loratadina Ranbaxy (FAQ)

Q: What is Loratadina Ranbaxy?

A: Loratadina Ranbaxy contains the active ingredient loratadine, which is an antihistamine medication. Antihistamines work by blocking the effects of a substance called histamine in the body. Histamine is naturally released during an allergic reaction and can cause symptoms like itching, sneezing, and watery eyes.

Q: What is Loratadina Ranbaxy used for?

A: Loratadina Ranbaxy is approved to temporarily relieve symptoms associated with seasonal allergic rhinitis, commonly referred to as hay fever. These symptoms may include sneezing, runny nose, and itching of the eyes or nose.

Q: How long does Loratadina Ranbaxy take to work?

A: The time it takes for Loratadina Ranbaxy to begin having an effect can vary among individuals. In clinical studies, effects were typically observed within a few hours of administration. Its effects are intended to last for approximately 24 hours.

Q: Is Loratadina Ranbaxy safe to take every day?

A: Loratadina Ranbaxy, when taken at the approved dosage, is generally considered suitable for daily use for seasonal allergy symptom relief. It is important to follow the directions provided on the product labeling or consult a healthcare provider regarding appropriate duration of use.

Q: Are there common side effects associated with Loratadina Ranbaxy?

A: Like all medications, Loratadina Ranbaxy may be associated with side effects, although not everyone experiences them. The most commonly reported side effects include headache, fatigue, and dry mouth. If you experience any severe or concerning side effects, discontinue use and seek professional medical attention.

Q: Can I take Loratadina Ranbaxy with other allergy medications?

A: Before combining Loratadina Ranbaxy with any other medication, including other allergy treatments, cold remedies, or over-the-counter drugs, it is recommended to speak with a pharmacist or healthcare provider. This is important to help avoid potential drug interactions or the risk of taking too much of a similar active ingredient.

Storage and Handling

Loratadine tablets must be stored at controlled room temperature, specifically maintained between 20 to 25 C (68 to 77 F). The medication must be protected from excessive moisture. To maintain stability, the product should be stored in its original container, which must remain intact. If supplied as a liquid, the formulation must be protected from freezing.

Child Safety and Disposal

A critical storage requirement is to keep the product out of the sight and reach of children.

For disposal, regulatory instructions state that unused or expired medicine must not be thrown away via wastewater or household waste. Instead, consult a pharmacist for instructions on how to properly discard the product, typically through a local drug take-back or collection program.